New executive director named for UC Davis Comprehensive Cancer Center

Andrew Bresnahan will join UC Davis Health as the executive director of UC Davis Comprehensive Cancer Center and Cell and Gene Therapy, effective January 27, 2025.

Bresnahan brings more than 15 years of progressive leadership experience, most recently serving as the director of oncology at Northwestern Memorial Hospital. There, he led operations for the inpatient and outpatient cell therapy departments, oncology services, apheresis center, and cell lab. He played a pivotal role in establishing CAR-T, TIL, and non-malignant programs, advancing cell and gene therapy initiatives, and ensuring compliance with industry regulatory and accreditation standards.

"We are thrilled to welcome Andrew to UC Davis Health as we continue to advance patient-centered, comprehensive cancer care and innovative therapies for our community,” said cancer center Physician-in-Chief David Tom Cooke. “His unique expertise in oncology and cell and gene therapy will help us expand access, improve operational efficiencies, and enhance the experiences of our patients, providers, and staff."

Cooke expressed his heartfelt gratitude to Carla Martin for her exceptional leadership as interim executive director.

UC Davis Health Chief Operating Officer Michael Condrin announced the news, saying Bresnahan’s expertise extends to strategic planning, regulatory compliance, and building innovative care models. His leadership has consistently focused on enhancing patient-centered care, optimizing operational efficiencies, and fostering multidisciplinary collaboration.

“We are excited to welcome Andrew’s vision and expertise as he takes on this critical role,” said Condrin, who is also the chief administrator of the UC Davis Medical Center.